Dotmatics Collaborates with HighRes Biosolutions to Provide Single Software Interface for Lab Digitalization

  Integration of Dotmatics’ ELN with HighRes Biosolutions’ Cellario instrument control software will streamline experiments and workflows Scientists will be able to plan experiments and run instruments from the ELN Bishop’s Stortford, UK, and  Beverly, MA, 25 January 2021: Dotmatics Ltd, a scientific informatics software and services company that is driving the automation of laboratory […]

HighRes Biosolutions and Novo Nordisk Partner to Transform Drug Discovery in Automated Lab of the Future

Beverly, US, 24 January 2020: HighRes Biosolutions and Novo Nordisk A/S today announced that they will collaborate to design a state-of-the-art robotic platform for high-throughput biologics engineering and characterisation. The integration of a multi-system robotics platform with sophisticated software control architecture will enable a digital transformation and accelerated discovery for Novo Nordisk’s peptide and large […]

HighRes Biosolutions and TetraScience integrate technology to provide R&D labs with next-generation lab automation.

BEVERLY, Mass. and BOSTON, May 22, 2019 /PRNewswire/ — HighRes Biosolutions and TetraScience announce a new partnership to integrate their flagship products to automate data collection and manipulation processes in life sciences lab automation. The integration streamlines data collection, aggregation, and transportation from HighRes’ robotics platform, moving data automatically to downstream informatics applications via the TetraScience Data Integration Platform. Popular […]

Beverly pharma robotics company names new CEO

By Kelly J. O’Brien – Technology Reporter, Boston Business Journal December 20, 2018, 4:39pm EST Beverly-based HighRes Biosolutions Inc. has named a new CEO as it aims to expand the reach of its robotic arms throughout the pharmaceutical world. Ira Hoffman, formerly the company’s president, will become CEO of February 1, replacing current CEO Peter […]

Controlling Costs of Drug Discovery Through Automation

Written by: Peter Harris, CEO, HighRes Biosolutions The escalating cost of discovering new biopharmaceutical therapies is a well-known and long-standing problem. Recent estimates by the Tufts Center for the Study of Drug Development put the cost of developing and getting approval for a new drug just shy of $3 billion1. The underlying buildup of costs, […]

What’s the future of lab automation?

Lab automation has come a long way since the days of industrial robots, with new advancements increasing efficiency between systems and workers. Peter Harris, HighRes Biosolutions, discusses how far the sector has moved and what the future holds. The use of automation and robotics in scientific research has been around for quite some time, starting […]

Robotics Business Review

HighRes Biosolutions Accelerates Pharmaceutical Research With Automation

As an integrator, HighRes Biosolutions intimately knows its customers’ needs, as the biopharmaceuticals industry looks to save money and speed testing with robots.’ The pharmaceuticals industry is ideal for robotics, requiring precision, repeatability, and strict standards compliance. Scientists working on drug discovery, molecular diagnostics, and other research rely on integrators such as HighRes Biosolutions Inc. […]

Bloomberg Businessweek

These Modular Lab Systems Could Further Automate Drug Development

Modular automation from HighRes Biosolutions lets lab technicians quickly disconnect, move, and reconnect mobile carts containing robotic arms and other devices, expanding the range of experiments that can be performed at a single site. The Benefit One HighRes system can do the work of 20 to 30 lab techs with fewer errors, enabling faster development […]

Wall Street Journal

How Robots Are Making Better Drugs, Faster

Robotic lab techs don’t need to stop for rest. Unlike humans, they can shuttle samples 24/7. Featured on By Daniela Hernandez The scientist hunched over beakers, conducting drug research by hand, may soon be a memory. Companies like Eli Lilly & Co. and GlaxoSmithKline PLC are investing in automation with the hope of transforming […]

Request Info